Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDA53: Ibrutinib + Daratumumab in R/R CLL with p53 Dysfunction
NCT03734198Phase 2Active, not recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Dec 2018
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in chronic lymphocytic leukemia (CLL), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Complete Response Rate at 12 months. Started Dec 2018; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03734198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734198.